Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate

Abstract

This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.

1 - 5 . (canceled) 
     
     
         6 . An ophthalmic pharmaceutical composition comprising as active ingredient a combination of:
 a) glycine and proline; and   b) sodium hyaluronate.   
     
     
         7 . The ophthalmic pharmaceutical composition of  claim 6 , the composition further comprising as active ingredient:
 c) lysine and leucine.   
     
     
         8 . The ophthalmic pharmaceutical composition of  claim 6 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate are comprised within the following percentage ranges by weight:
 glycine 0.01 to 0.5%;   L-proline: 0.09 to 0.06%, and   sodium hyaluronate; 0.5 to 0.1%.   
     
     
         9 . The ophthalmic pharmaceutical composition of  claim 7 , wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine are comprised within the following percentage ranges by weight:
 L-lysine hydrochloride: 0.01 to 0.02%; and   L-leucine: 0.02 to 0.005%.   
     
     
         10 . The ophthalmic pharmaceutical composition of  claim 6 , wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate have the following percentage ranges by weight:
 glycine: 0.1%   L-proline: 0.075%; and   sodium hyaluronate: 0.3%.   
     
     
         11 . The ophthalmic pharmaceutical composition of  claim 7 , wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine have the following percentage ranges by weight:
 L-lysine hydrochloride: 0.014%, and   L-leucine: 0.011%   
     
     
         12 . The ophthalmic pharmaceutical composition of  claim 6 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel. 
     
     
         13 . The ophthalmic pharmaceutical composition of  claim 7 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel. 
     
     
         14 . The ophthalmic pharmaceutical composition of  claim 8 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel. 
     
     
         15 . The ophthalmic pharmaceutical composition of  claim 9 , wherein the composition is in form of eyedrops, artificial tears, ointment or gel 
     
     
         16 . The ophthalmic pharmaceutical composition of  claim 10  wherein the composition is in form of eyedrops, artificial tears, ointment or gel. 
     
     
         17 . The ophthalmic pharmaceutical composition of  claim 11  wherein the composition is in form of eyedrops, artificial tears, ointment or gel. 
     
     
         18 . A method to treat a corneal ulceration in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 6 .   
     
     
         19 . A method to treat a corneal ulceration in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 7 .   
     
     
         20 . A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 6 .   
     
     
         21 . A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 7 .   
     
     
         22 . A method to treat symptoms of dry eye in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 6 .   
     
     
         23 . A method to treat symptoms of dry eye in a patient, the method comprising
 administering to the patient the ophthalmic pharmaceutical composition of  claim 7 .